Ponesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P1 receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. Results from the OPTIMUM phase III trial demonstrated the superiority of ponesimod over teriflunomide on disease activity markers, without unexpected safety concerns. Furthermore, the drug is eliminated within 1 week of discontinuation, allowing for the reversibility of its effects. Ponesimod was recently approved in both the U.S. and E.U. for the treatment of relapsing forms of multiple sclerosis. This review summarizes the pharmacological characteristics of ponesimod and the main studies that led to its approval.

Ponesimod to treat multiple sclerosis / Ianniello, A; Pozzilli, C. - In: DRUGS OF TODAY. - ISSN 1699-3993. - 57:12(2021), pp. 745-758. [10.1358/dot.2021.57.12.3353166]

Ponesimod to treat multiple sclerosis

Ianniello, A
Primo
;
Pozzilli, C
Ultimo
2021

Abstract

Ponesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P1 receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the entry of autoreactive cells into the central nervous system. Unlike fingolimod, ponesimod does not require monitoring of the first dose, thanks to a 14-day uptitration regimen, which markedly reduces the incidence of cardiodynamic effects related to the initiation of therapy. Results from the OPTIMUM phase III trial demonstrated the superiority of ponesimod over teriflunomide on disease activity markers, without unexpected safety concerns. Furthermore, the drug is eliminated within 1 week of discontinuation, allowing for the reversibility of its effects. Ponesimod was recently approved in both the U.S. and E.U. for the treatment of relapsing forms of multiple sclerosis. This review summarizes the pharmacological characteristics of ponesimod and the main studies that led to its approval.
2021
ACT-128800; demyelinating diseases; multiple sclerosis; ponesimod; sphingosine-1-phosphate (S1P) receptor modulators; treatment of autoimmune diseases
01 Pubblicazione su rivista::01a Articolo in rivista
Ponesimod to treat multiple sclerosis / Ianniello, A; Pozzilli, C. - In: DRUGS OF TODAY. - ISSN 1699-3993. - 57:12(2021), pp. 745-758. [10.1358/dot.2021.57.12.3353166]
File allegati a questo prodotto
File Dimensione Formato  
Ianniello_Ponesimod_2021.pdf

solo gestori archivio

Note: Ianniello_Ponesimod_2021
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 268.94 kB
Formato Adobe PDF
268.94 kB Adobe PDF   Contatta l'autore
Ponesimod to treat Multiple Sclerosis_revised draft.pdf

accesso aperto

Note: Ianniello_Ponesimod_2021_preprint
Tipologia: Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza: Creative commons
Dimensione 281.28 kB
Formato Adobe PDF
281.28 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1669823
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact